Tag Archives: Tagrisso

April, 2018

December, 2017

October, 2017

July, 2017

June, 2017

March, 2017

  • 31 March

    FDA Grants Full Approval to AstraZeneca’s NSCLC Drug Tagrisso

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed …

July, 2016

February, 2016

  • 3 February

    AstraZeneca’s Tagrisso Wins European Approval for Treatment of Lung Cancer

    AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is indicated for patients with T790M …

November, 2015